SCA
UTHR icon

Sage Capital Advisors’s United Therapeutics UTHR Stock Holding History

Sage Capital Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-27,064
Closed -$3.04M – 92
2018
Q1 		$3.04M Buy
27,064
+69
+0.3% +$8.77K 2.15% 17
2017
Q4 		$3.99M Buy
26,995
+152
+0.6% +$19.3K 2.59% 11
2017
Q3 		$3.15M Buy
+26,843
New +$3.43M 2.21% 13

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sage Capital Advisors's UTHR Position: Q2 2018 in Review

Sage Capital Advisors sold out of United Therapeutics (UTHR) in Q2 2018, closing a stake of 27,064 shares — an estimated $3.04M sold.

Sage Capital Advisors first reported a position in UTHR in Q3 2017 and held it in 3 quarters. The position peaked at $3.99M in Q4 2017. 374 funds tracked by Wall St. Rank hold UTHR as of Q2 2018.

  • Sage Capital Advisors reported no remaining United Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Sage Capital Advisors sold 27,064 United Therapeutics shares in Q2 2018, an estimated $3.04M.
  • Sage Capital Advisors first reported a position in United Therapeutics in Q3 2017 and held it in 3 quarters.
  • Sage Capital Advisors's United Therapeutics position peaked at $3.99M in Q4 2017.
  • 374 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2018.

Based on Sage Capital Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.